ALX ONCOLOGY HOLDINGS INC (ALXO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ALX ONCOLOGY HOLDINGS INC (ALXO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001810182 false 0001810182 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
How this was made
The 30-second read
Why it matters
The company reported a board chairman resignation (Corey Goodman) and appointment of Scott Garland as chairman, along with updated committee chair assignments.
Market read
This is a governance update that may affect sentiment and oversight expectations, but it does not include new financial guidance, deals, or regulatory/clinical catalysts.
What to watch
Traders should check whether the committee chair roles (audit/comp/gov) changed materially, as that can affect oversight intensity even without operational disclosures.
Background
The filing is an SEC Form 8-K (Item 5.02) reporting director/officer changes and related committee composition updates.
Ticker impact
ALX Oncology disclosed Corey Goodman’s resignation as board chairman and named Scott Garland as the new chairman effective June 29, 2026.
Likely limited near-term impact unless investors interpret the change as signaling broader strategic or governance issues.
The 8-K is a governance/committee reconstitution item (Item 5.02) with no stated disagreement, disputes, or new business terms; impact is therefore mostly sentiment/governance-driven.
Market effects
Minimal sector read-through; this is company-specific governance housekeeping rather than a biotech sector catalyst.
No clear regional spillover beyond Nasdaq-listed small/mid-cap sentiment.
Primarily local to the issuer’s governance; no global market linkage indicated.
Counterpoint
Investors may overreact to a chairman change; since Goodman cited personal reasons and no disagreements, the market signal could be noise.
Key entities
- companyALX Oncology Holdings Inc.
Nasdaq-listed biotech issuer filing the 8-K reporting board leadership and committee changes.
- personCorey Goodman, Ph.D.
Resigned as Chairman of the board and from board committees effective June 29, 2026; stated personal reasons and no disagreements.
- personScott Garland
Independent director appointed as Chairman effective June 29, 2026; also assigned to multiple committee roles.